It Takes Guts: Psychedelic Treatment Approaches to Autoimmune Disorders

There is much research into psychedelic treatment of mental disorders, but psychedelics might be effective in treating autoimmune disorders as well.

-

After being banned in the United States in 1970, psychedelic compounds have recently made their way back into the attention sphere of the mainstream medical community for their efficacy in treating mental illnesses such as PTSD, depression, and anxiety.1,2 Current research into psychedelic drugs primarily focuses on their potential in treating mental illnesses, however, there exists some evidence for their potential in treating another field of illnesses called autoimmune disorders. In this article, the potential link between autoimmune disorders and mental illnesses will be explored, along with possible biochemical pathways that might explain psychedelic’s efficacy in treating both types of conditions.

What are Autoimmune Disorders?

Autoimmunity is when the body’s immune system malfunctions and attacks healthy tissue. The link between autoimmune disorders and mental disorders has received increasing attention in the past twenty years.3 Being diagnosed with an autoimmune condition increases one’s chances of being diagnosed with a mood disorder.4 Research into how these two disorders are related has revealed several potential pathways, ranging from chronic inflammation, dysregulation of the hypothalamic-pituitary-adrenal axis (HPA axis), disruptions in the gut microbiome, and chronic stress and trauma.5-6 Examining these potential causes, there are many points in which psychedelics might be acting on to explain their treatment efficacy.

Psychedelic Pharmacology

Classic psychedelics exhibit agonistic activity at various serotonin (5-HT) receptors, with the most commonly shared feature being 5-HT2A receptor agonist binding. The table below details some common psychedelics and the receptor subtypes they are known to bind to.7-11

Psychedelic5-HT Subtype AffinityOther Receptor Affinity
LSD1A, 1B, 1D, 1E, 2A, 2B, 2C, 5A, 6, and 7Dopaminergic receptors subtypes D1 and D2
Psilocin1A, 1D, 2A, 2CAdrenergic alpha A and B, dopamine D3, histamine H1
DMT1A, 1B, 1D, 2A, 2B, 2C, 5A, 6 and 7Glutamate receptors, dopamine, acetylcholine, and the opioid-like receptor Sig1R

Other psychedelic compounds like ketamine affect N-Methyl-D-aspartate (NMDA) receptors as well, which research shows might affect autoimmune disorders via its effect on glutamate pathways.10,12

Inflammation and Immune Modulation

Research has shown that chronic inflammation plays a key role in autoimmune disorders.7 Dysregulated inflammation is present in many autoimmune disorders, such as lupus, rheumatoid arthritis, systemic sclerosis, and Sjögren’s syndrome.13-17 Correspondingly, there has been much research into the 5HT system and its inflammation and immune regulation properties.12,18,20-22 Sig1R, another receptor that psychedelics like DMT effect, also modulates inflammatory and immune responses.23,24-26 Via their effect on the 5HT system and Sig1R system, psychedelics might have anti-inflammatory properties that could explain their potential in treating autoimmune disorders.27-29

Trauma and Stress

Another pathway where mental disorders and autoimmune disorders might be linked lies in stressful and traumatic childhood events. Adverse childhood experiences (ACEs) are strongly correlated with autoimmune disorders in later life.30-32 Research into the effect that psychological stress has on the immune system reveals that psychological stress can compromise the immune system function as well.33-37 This leads to disorders such as food sensitivity, HPA axis dysregulation, and leaky gut syndrome, all of which are strongly correlated with autoimmune disorders.34-38 This research hints at how psychedelic treatment of trauma-related illnesses might also improve physiological ailments related to trauma.39-41

Glutamate and Brain-Derived Neurotrophic Factor

Glutamate excitotoxicity involves overactive glutamate receptors in the brain. Chronic excitation of glutamate receptors can contribute to oxidative stress, causing brain damage.38,42,43 Glutamate excitotoxicity is related to depression, addiction, and other neurodegenerative diseases.42-44 Examining ketamine’s effect on NMDA glutamate receptors, it is possible that ketamine’s effect on depression might be related to glutamate regulation.10 Agonists of the Sig1R receptor subtype have also shown to be neuroprotective glutamate excitotoxicity.45,46 Also, DMT has been shown to have potent neuroprotective effects via the Sig1R.29

Psychedelics might increase levels of brain-derived neurotrophic factor (BDNF) gene expression, which facilitates neurogenesis.47-49 Low BDNF expression has been linked to depression, anxiety, schizophrenia, and neurodegenerative diseases.50-53 This pathway is related to 5-HT2A receptor agonist activity of classic psychedelics – in an experiment, administration of a 5-HT2A antagonist reduced the neuroplastic effects of classic psychedelics LSD, DMT, and DOI.48 It is feasible that the BDNF-upregulating qualities of psychedelics could reduce the inflammatory effects of glutamate excitotoxicity in autoimmune disease.54

Gut Microbiome Dysregulation

The gut microbiome refers to the microorganisms present in the gastrointestinal tract (GIT). The gut microbiome produces many neurotransmitters in the body, including dopamine, serotonin, norepinephrine, and gamma-aminobutyric acid (GABA).55 Chronic infections with bacteria, fungi, and viruses are common in those with autoimmune disorders.13,54,56-59 Microbiome bacterial populations appear to play a significant role in a number of immune responses, and influence the presence of autoimmune disorders.1

Psychedelic plants like ayahuasca and peyote have been shown to exhibit anti-microbial properties, which may explain how psychedelics can effectively treat autoimmune conditions.27,60-62 Also, experiments that introduced serotonin to the gut microbiome indicate the presence of a bidirectional signalling system between the host serotonin system and the gut microbiome.63 This highlights the potential for psychedelic serotonin analogues psilocybin, DMT, and 5-MeO-DMT interacting with bacterial receptors.

Lastly, the psychological benefits of psychedelics may indirectly alter microbial communities in the GIT via induced changes in vagal nerve tone and stress response.34,64 Several studies examining the effects of chronic stress and PTSD on microbiome pattern associations found a link between stress and microbiome health.65,66 The psychological and neurological benefits from a psychedelic experience may cause biochemical cascades in the HPA axis and the nervous system, which may influence the ecology of microbial populations.

Conclusion

Autoimmune disorders involve a malfunction of the body’s immune system, causing it to attack the body it is meant to protect. While the causes of autoimmune diseases are varied, several pathways have been proposed involving neurotransmitter dysfunction, gut microbiome dysfunction, and an assortment of other dysregulations present in the nervous system’s biochemistry.

There appears to be an immensely complex biochemical network involving the peripheral nervous system, the gut microbiome, and the immune system. This helps explain psychedelics’ well-known efficacy in treating mental illnesses and also highlights the potential for psychedelics to treat autoimmune disorders.

Further research into the potential biochemical pathways that connect these areas of the body may provide more effective psychedelic treatment programs for mental illnesses. Also, these studies lay the groundwork for using psychedelics for treating of a whole other class of disorders involving the immune system.

Comments

11 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
V. Winger.
7 months ago

Interesting. Going on 13 years of autoimmune diseases I see a correlation between stress events, ptsd, depression, food sensitivity and flairs of inflammation, pain and declining physical health.
Please study this hypothesis. We need hope.

Dayton
7 months ago

Interesting, I have psoriatic arthritis, undiagnosed gut issues, and am currently on a biologic.
Sign me up!

Purples
7 months ago

Fascinating article, thank you. I’m always worried that sketching out potential physiological pathways and speculating as to modes of action, are sometimes taken as proxy evidence of clinical effectiveness. Whilst describing biological plausibility is important, this never answers the fundamental question, ‘does it work’?

C. Thompson
7 months ago

I think you may have forgotten to include the most significant citation.

Thompson C, Szabo A. Psychedelics as a novel approach to treating autoimmune conditions. Immunol Lett. 2020 Dec;228:45-54. doi: 10.1016/j.imlet.2020.10.001. Epub 2020 Oct 7. PMID: 33035575.

https://pubmed.ncbi.nlm.nih.gov/33035575/

Please remember to give credit where it is due. 😉

Sincerely,

Caitlin Thompson and Atilla Szabo (the authors of the paper this article is apparently based off of)

Harriet
6 months ago
Reply to  C. Thompson

As a fellow scientist I wouldn’t assume that lightly – it’s possible that the author wasn’t even aware of such a recent paper. I know the frustration of feeling like you weren’t given credit, but many of the cited papers contain similar information. I’d make absolutely certain before hastily and publicly implying that someone plagiarized.

Caitlin Thompson
6 months ago
Reply to  Harriet

If you view our paper, you’ll see the headings, content and citations are almost identical. Maybe it’s a coincidence.

Looking for answer to UC
6 months ago

This article is true. It does help. It helped me with my darn UC. Been sick w UC for over a year and tired of the med side effects. Im looking to get off the meds for UC. I know CBD helps but it only goes so far. My next quest is to microdose to a point when the inflammation can stay away. Or some other answer for this nonsense..UC

Looking for answers

pickle
6 months ago

Straight up, my inflammation goes away with a hit of the DMT pen.

Helena
5 months ago

And what about Diabetes Mellitus I.type? It is autoimmune disorder too. Are there any results?

Janice Mader
5 months ago

Diagnosed three years ago with rheumatoid arthritis after receiving 11 vaccinations prior to going to India to do mission surgeries. Have sought natural therapies only as traditional medicine is a complete fail with this disease. I would be very interested in clinical trials if and when they come to fruition. I have been contacting my congressman and women and actively advocating for the medicinal use. Thank you for furthering the cause.

Alex M
16 hours ago

My mother was diagnosed with polymyositis and then IBM within the last 10 years by some of the best medical facilities across the country, including Johns Hopkins. Her body is slowly shutting down as a result and nothing in western medicine has helped, including physical therapy. I firmly believe this is a lifestyle disease from a long history of anxiety, depression, fear, resentment, etc. as a result of the emotional trauma the “system” produces. No one ever mentioned to her she might have a mental disorder or suffer from PTSD. They told her the obvious and tried the worst drugs… Read more »

    References
  1. Nichols DE, Johnson MW, Nichols CD. Psychedelics as Medicines: An Emerging New Paradigm. Clin Pharmacol Ther. 2017;101(2):209-219. doi:10.1002/cpt.557
  2. Nutt D. Psychedelic drugs-a new era in psychiatry? Dialogues Clin Neurosci. 2019;21(2):139-147. https://www.ncbi.nlm.nih.gov/pubmed/31636488 doi:10.31887/dcns.2019.21.2/dnutt
  3. Siegmann E-M, Müller HHO, Luecke C, Philipsen A, Kornhuber J, Grömer TW. Association of Depression and Anxiety Disorders With Autoimmune Thyroiditis: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2018;75(6):577-584. doi:10.1001/jamapsychiatry.2018.0190
  4. Kosiewicz MM, Zirnheld AL, Alard P. Gut Microbiota, Immunity, and Disease: A Complex Relationship. Frontiers in Microbiology. 2011;2. doi:10.3389/fmicb.2011.00180
  5. Muzik O, Diwadkar VA. Hierarchical control systems for the regulation of physiological homeostasis and affect: Can their interactions modulate mood and anhedonia? Neurosci Biobehav Rev. 2019;105:251-261. doi:10.1016/j.neubiorev.2019.08.015
  6. Phillips BE, Garcia Figueroa Y, Trucco M, Giannoukakis N. Clinical Tolerogenic Dendritic Cells: Exploring Therapeutic Impact on Human Autoimmune Disease. Front Immunol. 2017;8:1279. doi:10.3389/fimmu.2017.01279
  7. de la Torre R, Farré M, Roset PN, et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004;26(2):137-144. doi:10.1097/00007691-200404000-00009
  8. Hintzen A, Passie T. The Pharmacology of LSD. OUP Oxford; 2010. https://books.google.com/books/about/The_Pharmacology_of_LSD.html?hl=&id=KTyC-e7NmI8C
  9. Abdallah CG, Adams TG, Kelmendi B, Esterlis I, Sanacora G, Krystal JH. KETAMINE’S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS. Depression and Anxiety. 2016;33(8):689-697. doi:10.1002/da.22501
  10. Petrocchi JA, de Almeida DL, Paiva-Lima P, et al. Peripheral antinociception induced by ketamine is mediated by the endogenous opioid system. Eur J Pharmacol. 2019;865:172808. doi:10.1016/j.ejphar.2019.172808
  11. Besnard J, Ruda GF, Setola V, et al. Automated design of ligands to polypharmacological profiles. Nature. 2012;492(7428):215-220. doi:10.1038/nature11691
  12. Anaya J-M, Ramirez-Santana C, Alzate MA, Molano-Gonzalez N, Rojas-Villarraga A. The Autoimmune Ecology. Front Immunol. 2016;7:139. doi:10.3389/fimmu.2016.00139
  13. Burska A, Boissinot M, Ponchel F. Cytokines as Biomarkers in Rheumatoid Arthritis. Mediators of Inflammation. 2014;2014:1-24. doi:10.1155/2014/545493
  14. Stypińska B, Paradowska-Gorycka A. Cytokines and MicroRNAs as Candidate Biomarkers for Systemic Lupus Erythematosus. Int J Mol Sci. 2015;16(10):24194-24218. doi:10.3390/ijms161024194
  15. Salvi V, Gianello V, Tiberio L, Sozzani S, Bosisio D. Cytokine Targeting by miRNAs in Autoimmune Diseases. Frontiers in Immunology. 2019;10. doi:10.3389/fimmu.2019.00015
  16. Moudgil KD, Choubey D. Cytokines in Autoimmunity: Role in Induction, Regulation, and Treatment. Journal of Interferon & Cytokine Research. 2011;31(10):695-703. doi:10.1089/jir.2011.0065
  17. Dos Santos RG, Valle M, Bouso JC, et al. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine. J Clin Psychopharmacol. 2011;31(6):717-726. doi:10.1097/JCP.0b013e31823607f6
  18. Chen M-H, Li C-T, Lin W-C, et al. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study. Psychiatry Res. 2018;269:207-211.
  19. Dürk T, Panther E, Müller T, et al. 5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypes. Int Immunol. 2005;17(5):599-606. doi:10.1093/intimm/dxh242
  20. Casas-Engel M de las, de las Casas-Engel M, Domínguez-Soto A, et al. Serotonin Skews Human Macrophage Polarization through HTR2B and HTR7. The Journal of Immunology. 2013;190(5):2301-2310. doi:10.4049/jimmunol.1201133
  21. Szabo A, Gogolak P, Koncz G, et al. Immunomodulatory capacity of the serotonin receptor 5-HT2B in a subset of human dendritic cells. Scientific Reports. 2018;8(1). doi:10.1038/s41598-018-20173-y
  22. Albayrak Y, Hashimoto K. Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders. Adv Exp Med Biol. 2017;964:153-161. doi:10.1007/978-3-319-50174-1_1
  23. Jia J, Cheng J, Wang C, Zhen X. Sigma-1 Receptor-Modulated Neuroinflammation in Neurological Diseases. Front Cell Neurosci. 2018;12:314. doi:10.3389/fncel.2018.00314
  24. Penke B, Fulop L, Szucs M, Frecska E. The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases. Curr Neuropharmacol. 2018;16(1):97-116. doi:10.2174/1570159X15666170529104323
  25. Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol. 2013;100:15-29. doi:10.1016/j.pneurobio.2012.09.001
  26. Szabo A. Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities. Front Immunol. 2015;6:358. doi:10.3389/fimmu.2015.00358
  27. Szabo A, Kovacs A, Frecska E, Rajnavolgyi E. Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells. PLoS One. 2014;9(8):e106533. doi:10.1371/journal.pone.0106533
  28. Nardai S, László M, Szabó A, et al. N,N-dimethyltryptamine reduces infarct size and improves functional recovery following transient focal brain ischemia in rats. Exp Neurol. 2020;327:113245. doi:10.1016/j.expneurol.2020.113245
  29. Dube SR, Fairweather D, Pearson WS, Felitti VJ, Anda RF, Croft JB. Cumulative childhood stress and autoimmune diseases in adults. Psychosom Med. 2009;71(2):243-250. doi:10.1097/PSY.0b013e3181907888
  30. DeQuattro K, Trupin L, Li J, et al. Relationships Between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus. Arthritis Care Res . 2020;72(4):525-533. doi:10.1002/acr.23878
  31. Miller GE, Chen E, Parker KJ. Psychological stress in childhood and susceptibility to the chronic diseases of aging: Moving toward a model of behavioral and biological mechanisms. Psychological Bulletin. 2011;137(6):959-997. doi:10.1037/a0024768
  32. Fali T, Vallet H, Sauce D. Impact of stress on aged immune system compartments: Overview from fundamental to clinical data. Exp Gerontol. 2018;105:19-26. doi:10.1016/j.exger.2018.02.007
  33. Farzi A, Fröhlich EE, Holzer P. Gut Microbiota and the Neuroendocrine System. Neurotherapeutics. 2018;15(1):5-22. doi:10.1007/s13311-017-0600-5
  34. McEwen BS. Allostasis and the Epigenetics of Brain and Body Health Over the Life Course: The Brain on Stress. JAMA Psychiatry. 2017;74(6):551-552. doi:10.1001/jamapsychiatry.2017.0270
  35. Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nature Reviews Immunology. 2017;17(4):233-247. doi:10.1038/nri.2017.1
  36. Obrenovich M. Leaky Gut, Leaky Brain? Microorganisms. 2018;6(4):107. doi:10.3390/microorganisms6040107
  37. Morris G, Berk M, Maes M, Carvalho AF, Puri BK. Socioeconomic Deprivation, Adverse Childhood Experiences and Medical Disorders in Adulthood: Mechanisms and Associations. Mol Neurobiol. 2019;56(8):5866-5890. doi:10.1007/s12035-019-1498-1
  38. Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655-663. doi:10.1017/S0033291718001356
  39. Silva FS da, da Silva FS, Silva EAS, et al. Acute effects of ayahuasca in a juvenile non-human primate model of depression. Brazilian Journal of Psychiatry. 2019;41(4):280-288. doi:10.1590/1516-4446-2018-0140
  40. Galvão AC de M, de Almeida RN, Silva EADS, et al. Cortisol Modulation by Ayahuasca in Patients With Treatment Resistant Depression and Healthy Controls. Front Psychiatry. 2018;9:185. doi:10.3389/fpsyt.2018.00185
  41. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflügers Archiv - European Journal of Physiology. 2010;460(2):525-542. doi:10.1007/s00424-010-0809-1
  42. Kostic M, Zivkovic N, Cvetanovic A, Stojanovic I, Colic M. IL-17 signalling in astrocytes promotes glutamate excitotoxicity: Indications for the link between inflammatory and neurodegenerative events in multiple sclerosis. Mult Scler Relat Disord. 2017;11:12-17. doi:10.1016/j.msard.2016.11.006
  43. Dantzer R, Walker AK. Is there a role for glutamate-mediated excitotoxicity in inflammation-induced depression? Journal of Neural Transmission. 2014;121(8):925-932. doi:10.1007/s00702-014-1187-1
  44. Brimson JM, Safrany ST, Qassam H, Tencomnao T. Dipentylammonium Binds to the Sigma-1 Receptor and Protects Against Glutamate Toxicity, Attenuates Dopamine Toxicity and Potentiates Neurite Outgrowth in Various Cultured Cell Lines. Neurotox Res. 2018;34(2):263-272. doi:10.1007/s12640-018-9883-5
  45. Shen Y-C, Wang Y-H, Chou Y-C, et al. Dimemorfan protects rats against ischemic stroke through activation of sigma-1 receptor-mediated mechanisms by decreasing glutamate accumulation. J Neurochem. 2008;104(2):558-572. doi:10.1111/j.1471-4159.2007.05058.x
  46. Vaidya VA, Marek GJ, Aghajanian GK, Duman RS. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci. 1997;17(8):2785-2795. https://www.ncbi.nlm.nih.gov/pubmed/9092600 doi: 10.1523/j.neurosci.17-08-02785.1997
  47. Ly C, Greb AC, Cameron LP, et al. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018;23(11):3170-3182. doi:10.1016/j.celrep.2018.05.022
  48. Yang C, Shirayama Y, Zhang J-C, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5:e632. doi:10.1038/tp.2015.136
  49. Wang Y, Liu H, Du X-D, et al. Association of low serum BDNF with depression in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2017;41:73-78. doi:10.1016/j.parkreldis.2017.05.012
  50. Caviedes A, Lafourcade C, Soto C, Wyneken U. BDNF/NF-κB Signaling in the Neurobiology of Depression. Curr Pharm Des. 2017;23(21):3154-3163. doi:10.2174/1381612823666170111141915
  51. Rosso P, Iannitelli A, Pacitti F, et al. Vagus nerve stimulation and Neurotrophins: a biological psychiatric perspective. Neurosci Biobehav Rev. 2020;113:338-353. doi:10.1016/j.neubiorev.2020.03.034
  52. Fernandes BS, Molendijk ML, Köhler CA, et al. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. BMC Med. 2015;13:289. doi:10.1186/s12916-015-0529-7
  53. Hachem LD, Mothe AJ, Tator CH. Effect of BDNF and Other Potential Survival Factors in Models of In Vitro Oxidative Stress on Adult Spinal Cord–Derived Neural Stem/Progenitor Cells. BioResearch Open Access. 2015;4(1):146-159. doi:10.1089/biores.2014.0058
  54. Strandwitz P. Neurotransmitter modulation by the gut microbiota. Brain Research. 2018;1693:128-133. doi:10.1016/j.brainres.2018.03.015
  55. Dooley MA, Hogan SL. Environmental epidemiology and risk factors for autoimmune disease. Current Opinion in Rheumatology. 2003;15(2):99-103. doi:10.1097/00002281-200303000-00002
  56. Smyk DS. Helicobacter pylori and autoimmune disease: Cause or bystander. World Journal of Gastroenterology. 2014;20(3):613. doi:10.3748/wjg.v20.i3.613
  57. Blander JM, Magarian Blander J, Torchinsky MB, Campisi L. Revisiting the old link between infection and autoimmune disease with commensals and T helper 17 cells. Immunologic Research. 2012;54(1-3):50-68. doi:10.1007/s12026-012-8311-9
  58. Abdelhamid L, Luo XM. Retinoic Acid, Leaky Gut, and Autoimmune Diseases. Nutrients. 2018;10(8). doi:10.3390/nu10081016
  59. Chen D, Su A, Fu Y, et al. Harmine blocks herpes simplex virus infection through downregulating cellular NF-κB and MAPK pathways induced by oxidative stress. Antiviral Res. 2015;123:27-38. doi:10.1016/j.antiviral.2015.09.003
  60. Li Z, Chen S, Zhu S, Luo J, Zhang Y, Weng Q. Synthesis and Fungicidal Activity of β-Carboline Alkaloids and Their Derivatives. Molecules. 2015;20(8):13941-13957. doi:10.3390/molecules200813941
  61. McCleary JA, Sypherd PS, Walkington DL. Antibiotic activity of an extract of peyote (Lophophora William ii (Lemaire) Coulter). Economic Botany. 1960;14(3):247-249. doi:10.1007/bf02907956
  62. Fung TC, Vuong HE, Luna CDG, et al. Intestinal serotonin and fluoxetine exposure modulate bacterial colonization in the gut. Nat Microbiol. 2019;4(12):2064-2073. doi:10.1038/s41564-019-0540-4
  63. Bonaz B, Bazin T, Pellissier S. The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis. Front Neurosci. 2018;12:49. doi:10.3389/fnins.2018.00049
  64. Hemmings SMJ, Malan-Müller S, van den Heuvel LL, et al. The Microbiome in Posttraumatic Stress Disorder and Trauma-Exposed Controls: An Exploratory Study. Psychosom Med. 2017;79(8):936-946. doi:10.1097/PSY.0000000000000512
  65. Karl JP, Hatch AM, Arcidiacono SM, et al. Effects of Psychological, Environmental and Physical Stressors on the Gut Microbiota. Front Microbiol. 2018;9:2013. doi:10.3389/fmicb.2018.02013